Freestone Grove Partners LP purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 21,176 shares of the company's stock, valued at approximately $2,428,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Baker BROS. Advisors LP grew its position in shares of Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock worth $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC raised its position in shares of Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock valued at $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock valued at $487,685,000 after buying an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD grew its position in Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock worth $479,258,000 after buying an additional 1,061,957 shares in the last quarter. Finally, BlackRock Inc. acquired a new stake in Kymera Therapeutics during the second quarter worth approximately $635,067,000.
Wall Street Analyst Weigh In
KYMR has been the subject of several analyst reports. Royal Bank Of Canada cut Kymera Therapeutics from an "outperform" rating to a "sector perform" rating and lifted their price objective for the company from $106.00 to $115.00 in a report on Monday, July 13th. Canaccord Genuity Group increased their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a "buy" rating in a report on Friday, June 26th. Morgan Stanley restated an "overweight" rating and issued a $135.00 price target on shares of Kymera Therapeutics in a research report on Thursday, August 6th. B. Riley Financial boosted their price target on Kymera Therapeutics from $117.00 to $155.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Finally, Guggenheim upped their price objective on shares of Kymera Therapeutics from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Kymera Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $127.17.
View Our Latest Report on Kymera Therapeutics
Kymera Therapeutics Price Performance
NASDAQ KYMR opened at $118.15 on Friday. The business has a fifty day moving average price of $112.78 and a two-hundred day moving average price of $93.61. The stock has a market capitalization of $9.82 billion, a PE ratio of -36.47 and a beta of 1.95. Kymera Therapeutics, Inc. has a fifty-two week low of $39.84 and a fifty-two week high of $130.05.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. During the same quarter last year, the company posted ($0.95) EPS. The company's revenue for the quarter was up 465.2% compared to the same quarter last year. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the completion of the transaction, the director owned 240,123 shares of the company's stock, valued at approximately $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Bruce N. Jacobs sold 77,109 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the completion of the transaction, the chief financial officer directly owned 244,883 shares of the company's stock, valued at $28,151,749.68. This trade represents a 23.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,587,629 shares of company stock valued at $386,183,782 over the last ninety days. 15.98% of the stock is owned by insiders.
About Kymera Therapeutics
(
Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
